ENERGIZE THE FIGHT.
GIVE THE GIFT OF ENERGY
See how you can help families
like Patrick’s this holiday season
BREAKING NEWS: FDA APPROVES TK2D THERAPY
The U.S. Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease TK2d. “It’s hard to put into words what today’s decision means for patients living with TK2d,” said UMDF President and CEO Kristen Clifford. READ MORE >>
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
December 2025 Newsletter: NY Jets Bring Mito Awareness, New Research Grants, Clinical Trials Updates, and more
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.
UMDF Partners with MDA to Co-Fund Two New Mito Research Grants
UMDF has teamed up with the Muscular Dystrophy Association (MDA) to co-fund two new research projects to accelerate the development of promising therapies. Amongst the projects co-funded: Mariena D’Aurelio, PhD, Weill Medical College of Cornell University, will...
Ask the Mito Doc – Kygevvi
Ask the Mito Doc - Special Edition: FDA Approval of Kygevvi for TK2d All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Ask the Mito Doc - Special Edition: FDA...